Literature DB >> 29656609

Monocyte function in patients with myelodysplastic syndrome.

Daniel A Pollyea1, Brenna R Hedin2,3, Brian P O'Connor2,3,4,5, Scott Alper2,3,5.   

Abstract

Myelodysplastic syndrome (MDS) is a malignant hematopoietic stem cell disorder that frequently evolves into acute myeloid leukemia (AML). Patients with MDS are prone to infectious complications, in part due to the presence of severe neutropenia and/or neutrophil dysfunction. However, not all patients with neutropenia become infected, suggesting that other immune cells may compensate in these patients. Monocytes are also integral to immunologic defense; however, much less is known about monocyte function in patients with MDS. In the current study, we monitor the composition of peripheral blood monocytes and several aspects of monocyte function in MDS patients, including HLA-DR expression, LPS-induced inflammatory cytokine production, and phagocytosis. We find that monocytes from MDS patients exhibit relatively normal innate immune functions compared to monocytes from healthy control subjects. We also find that HLA-DR expression is moderately increased in monocytes from MDS patients. These results suggest that monocytes could compensate for other immune deficits in MDS patients to help fight infection. We also find that the range of immune functions in monocytes from MDS patients correlates with several key clinical parameters, including blast cell count, monocyte count, and revised International Prognostic Scoring System score, suggesting that disease severity impacts monocyte function in MDS patients. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  LPS; PBMC; human leukocyte antigen-antigen D related; myelodysplastic syndrome; phagocytosis

Mesh:

Substances:

Year:  2018        PMID: 29656609      PMCID: PMC6113098          DOI: 10.1002/JLB.5AB1017-419RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  40 in total

1.  Epidemiology and risk factors for infections in myelodysplastic syndromes.

Authors:  L R Sullivan; M A Sekeres; N K Shrestha; J P Maciejewski; R V Tiu; R Butler; S B Mossad
Journal:  Transpl Infect Dis       Date:  2013-09-09       Impact factor: 2.228

Review 2.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

3.  Defective chemotaxis in monosomy-7.

Authors:  P Ruutu; T Ruutu; P Vuopie; T U Kosunen; A de la Chapelle
Journal:  Nature       Date:  1977-01-13       Impact factor: 49.962

Review 4.  Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.

Authors:  Stuart L Goldberg; Er Chen; Mitra Corral; Amy Guo; Nikita Mody-Patel; Andrew L Pecora; Marianne Laouri
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

5.  Infection in the myelodysplastic syndromes.

Authors:  C Pomeroy; M M Oken; R E Rydell; G A Filice
Journal:  Am J Med       Date:  1991-03       Impact factor: 4.965

6.  Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome.

Authors:  Luana Fianchi; Giuseppe Leone; Brunella Posteraro; Maurizio Sanguinetti; Francesco Guidi; Caterina Giovanna Valentini; Maria Teresa Voso; Livio Pagano
Journal:  Leuk Res       Date:  2011-12-15       Impact factor: 3.156

7.  Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.

Authors:  Maria Teresa Voso; Pasquale Niscola; Alfonso Piciocchi; Luana Fianchi; Luca Maurillo; Pellegrino Musto; Livio Pagano; Giovanna Mansueto; Marianna Criscuolo; Maria Antonietta Aloe-Spiriti; Francesco Buccisano; Adriano Venditti; Andrea Tendas; Anna Lina Piccioni; Gina Zini; Roberto Latagliata; Nunzio Filardi; Alberto Fragasso; Susanna Fenu; Massimo Breccia
Journal:  Eur J Haematol       Date:  2015-06-21       Impact factor: 2.997

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  Function of neutrophils in preleukaemia.

Authors:  P Ruutu; T Ruutu; P Vuopio; T U Kosunen; A de la Chapelle
Journal:  Scand J Haematol       Date:  1977-04

10.  Myelodysplastic syndromes: incidence and survival in the United States.

Authors:  Xiaomei Ma; Monique Does; Azra Raza; Susan T Mayne
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

View more
  5 in total

1.  Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.

Authors:  Daniel A Pollyea; Chelsea Harris; Jennifer L Rabe; Brenna R Hedin; Lesly De Arras; Sigrid Katz; Emily Wheeler; Rafael Bejar; Matthew J Walter; Craig T Jordan; Eric M Pietras; Scott Alper
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

2.  Expression of mRNA TNFα and level of protein TNFα after exposure sCD40L in bone marrow mononuclear cells of myelodysplastic syndromes.

Authors:  Anggraini Iriani; Rahayuningsih D Setiabudy; Siti B Kresno; Aru W Sudoyo; Saptawati Bardosono; Andhika Rachman; Alida R Harahap; Mansyur Arief
Journal:  Stem Cell Investig       Date:  2021-03-29

3.  Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.

Authors:  Carolien Duetz; Theresia M Westers; Florentien E M In 't Hout; Eline M P Cremers; Canan Alhan; Bianca Venniker-Punt; Heleen A Visser-Wisselaar; Dana A Chitu; Aniek O de Graaf; Linda Smit; Joop H Jansen; Arjan A van de Loosdrecht
Journal:  Br J Haematol       Date:  2021-03-25       Impact factor: 6.998

4.  Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.

Authors:  Shuhui Zhang; Lin Zhou; Mengdi Zhang; Yuehua Wang; Mengqi Wang; Jincheng Du; Wenwen Gu; Fuguang Kui; Jiahuan Li; Shengnan Geng; Gangjun Du
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

5.  MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.

Authors:  Daniel A Pollyea; Hyun Min Kim; Brett M Stevens; Frank Fang-Yao Lee; Chelsea Harris; Brenna R Hedin; Jennifer R Knapp; Brian P O'Connor; Craig T Jordan; Eric M Pietras; Aik Choon Tan; Scott Alper
Journal:  J Leukoc Biol       Date:  2020-11-06       Impact factor: 6.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.